Patient P-02504
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
67%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 83 GI symptom burden −30% vs expected — GI Support Protocol GI-04
- Day 87 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 89 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 87.
Primary contributors, last 14 days
- Inflammatory activity-5
- Treatment adherence-3
- Nutritional resilience+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 74Result: symptom burden −30%
LIFE OS recommendation
Monitoring Escalation ME-01
76%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.8 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 30/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 83 bpm
- Wearable1,474 steps/day
- WearableShort sleep window
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 55
- Drug metabolism and exposure ↑20
- BloodToxicity index 48
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.4 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 55 ms
- Sleep
- 5.7 h
- Steps
- 2,206
- Resting HR
- 79 bpm
Daily log: GI score 50, nutritional resilience 48, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02410 | 51% | S01 | GI-04 | improved | 55 |
| P-02018 | 42% | S01 | GI-04 | improved | 46 |
| P-02054 | 34% | S01 | CR-01 | improved | 57 |
| P-02409 | 29% | S01 | SC-12 | no change | 54 |
| P-02307 | 23% | S01 | — | — | 55 |
| P-02437 | 23% | S01 | — | — | 64 |
| P-02598 | 23% | S01 | — | — | 53 |
| P-02217 | 22% | S01 | — | — | 61 |
| P-02276 | 22% | S01 | — | — | 57 |
| P-02550 | 22% | S01 | — | — | 70 |
| P-02041 | 21% | S01 | — | — | 27 |
| P-02087 | 21% | S01 | BR-03 | no change | 40 |